ZIM Labs Invests €300,000 in Latvian Subsidiary
By Ankur Chandra | Published at: Jun 19, 2025 03:44 PM IST
Mumbai, June 19 – ZIM Laboratories Ltd (NSE: ZIMLAB) stock price gained in morning trade today after the company confirmed the completion of a strategic capital infusion into its wholly owned subsidiary, SIA ZIM Laboratories Limited.
Aligned with ZIM Laboratories’ broader strategy to expand its pharmaceutical footprint across Europe and MENA (Middle East and North Africa), the expansion is to drive stronger revenues, boost global visibility, and enhance long-term shareholder value through broader market exposure.
The stock rose 1.47% to ₹107 as of 1:09 PM on June 19, up from its previous close of ₹105.38.
Investment Update Under SEBI Regulation 30
ZIM Labs, as part of a previously announced commitment made on March 28, 2025, has now concluded an equity investment of €300,000 (approximately ₹2.7 crore) in its Latvian arm. The company had earlier proposed an investment of up to €400,000.
Despite the reduced final amount, ZIM Labs continues to hold a 100% stake in SIA ZIM Laboratories Limited, ensuring full control over the overseas subsidiary. The company did not disclose further plans regarding the remaining €100,000 initially proposed for investment.
The company made the required disclosure in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Stock Market Reaction and Trade Snapshot
At 01:09 PM IST, shares of ZIM Labs were trading at ₹107, up 1.47% from the previous close.
| Price Data (₹) | Value |
|---|---|
| Previous Close | 105.38 |
| Open | 105.68 |
| Day’s High | 107.68 |
| Day’s Low | 105.01 |
| VWAP | 106.61 |
| 52-Week High (03-Sep-2024) | 128.90 |
| 52-Week Low (17-Mar-2025) | 79.49 |
| Market Metrics | Value |
|---|---|
| Market Cap (₹ Cr) | 519.27 |
| Free Float Market Cap (₹ Cr) | 215.28 |
| P/E Ratio (Adjusted) | 42.21 |
| Daily Volatility (%) | 2.67 |
| Annualised Volatility (%) | 51.01 |
Outlook
Reinforcing ZIM Labs’ international expansion strategy, the expansion helps the company leverage its Latvian subsidiary for deeper penetration into the European pharmaceutical market. The move has also lifted investor spirits, which has been highlighted by the intraday gain of the company’s stocks. The strategic move is expected to unlock broader market access, strengthen revenue potential, and drive sustained upward momentum in shareholder value over the coming quarters.
About the Company
ZIM Laboratories Ltd, listed on NSE and BSE since November 25, 2022, operates in the pharmaceutical sector, focusing on drug delivery solutions and novel formulations. The company has maintained a strong presence in regulated and semi-regulated markets through its R&D-backed product portfolio.
REF: https://nsearchives.nseindia.com/corporate/ZIMLAB_19062025100958_DisclosureUpdateonAcquisition.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
